Published in J Pediatr on August 01, 1999
Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect (2007) 0.79
Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis (2001) 3.11
Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA (1998) 2.50
Morbidity of pertussis in adolescents and adults. J Infect Dis (2000) 1.95
Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis (2011) 1.84
Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine (1997) 1.63
Identification of Bordetella pertussis infection by shared-primer PCR. J Clin Microbiol (1994) 1.49
Parental willingness to enter a child in a controlled vaccine trial. Clin Invest Med (1998) 1.24
Inactivated poliovirus vaccine: past and present experience. Vaccine (1996) 1.22
Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr (1992) 1.10
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr (1997) 1.10
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health (1998) 1.08
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J (1994) 1.07
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 1.05
Antibody response to bacteriophage hyaluronidase in acute glomerulonephritis after group A streptococcal infection. J Infect Dis (1987) 1.05
Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. CMAJ (1991) 1.04
An outbreak of diarrhea due to verotoxin-producing Escherichia coli in the Canadian Northwest Territories. Scand J Infect Dis (1994) 1.02
Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice. FEMS Microbiol Lett (2002) 1.01
Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. Infect Immun (1999) 0.98
Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J (1995) 0.97
Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. Am Rev Respir Dis (1983) 0.97
Exacerbations of asthma in adults during experimental rhinovirus infection. Am Rev Respir Dis (1985) 0.96
Infection of newborn piglets with Bordetella pertussis: a new model for pertussis. Infect Immun (2005) 0.95
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2012) 0.93
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Clin Exp Immunol (2006) 0.90
A swimming pool-associated outbreak of Cryptosporidiosis in British Columbia. Can J Public Health (1994) 0.89
Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA (2000) 0.89
DNA fingerprinting in investigation of apparent nosocomial acquisition of neonatal herpes simplex. J Pediatr (1980) 0.89
Serological correlates of immunity to Bordetella pertussis. Vaccine (1998) 0.88
Giardiasis outbreak from a chlorinated community water supply. Can J Public Health (1991) 0.88
Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii. Scand J Immunol (2009) 0.88
Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2007) 0.86
Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine (2001) 0.86
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J (2000) 0.85
Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine. Vaccine (2001) 0.84
Oculoglandular syndrome caused by Francisella tularensis. Clin Pediatr (Phila) (1985) 0.84
Comparison of parental and health care professional preferences for the acellular or whole cell pertussis vaccine. Pediatr Infect Dis J (1998) 0.84
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine (1995) 0.83
Bacterial cultures of the lower respiratory tract in normal volunteers with and without experimental rhinovirus infection using a plugged double catheter system. Am Rev Respir Dis (1982) 0.82
Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice. Can J Microbiol (2006) 0.82
Gemella species endocarditis in a child. Can J Infect Dis (2001) 0.82
Local adverse reactions to adsorbed DPT vaccine--Surrey, British Columbia. Can Dis Wkly Rep (1989) 0.82
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol (1991) 0.81
Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine (1999) 0.81
Reactogenicity to a live attenuated varicella vaccine in Canadian children. Can J Infect Dis (2000) 0.81
Enzyme-linked immunosorbent assay for identification and measurement of antibodies to group A streptococcal bacteriophage. J Lab Clin Med (1985) 0.80
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J (1999) 0.80
Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Can Dis Wkly Rep (1989) 0.80
Prevention of perinatal group B streptococcal infection: Management strategies. Can J Infect Dis (1997) 0.80
Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know. Hum Vaccin Immunother (2015) 0.79
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine (1996) 0.79
Breastfeeding and antibody responses to routine vaccination in infants. Lancet (1992) 0.79
[Quality evaluation of primary health care in an urban area of southern Brazil]. Rev Saude Publica (1994) 0.78
Rapid diagnosis of pertussis using the Chinese hamster ovary cell cytotoxicity assay. Eur J Clin Microbiol Infect Dis (1995) 0.77
Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Dev Biol Stand (1998) 0.77
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis (1995) 0.77
Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med (1994) 0.77
Absence of viremia in primary herpetic gingivostomatitis. Pediatr Infect Dis (1984) 0.76
Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis (1992) 0.76
Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J (1995) 0.76
Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine (1997) 0.76
Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med (1994) 0.76
Changing pattern of clinical illness in children with group A streptococcal bacteremia. Can J Infect Dis (1993) 0.75
Current practices of adjunctive therapy for pertussis at six Canadian tertiary care pediatric hospitals. Can J Infect Dis (1998) 0.75